4 studies found for:    anti-KIR mAb and myeloma | Phase 1, 2
Show Display Options
Rank Status Study
1 Completed
Has Results
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Anti-KIR (1-7F9)
2 Completed A Study Evaluating the Activity, Safety and Pharmacology of Two Doses of IPH2101, a Human Monoclonal Anti-KIR Antibody, in Patients With Multiple Myeloma in Stable Partial Response After a First Line Therapy
Condition: Multiple Myeloma
Intervention: Drug: IPH2101 Fully human anti-KIR monoclonal antibody
3 Active, not recruiting A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma;   Smoldering Multiple Myeloma
Intervention: Drug: (Anti-KIR)
4 Completed Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: alemtuzumab;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy

Indicates status has not been verified in more than two years